ライフサイエンスコーパス: cryptogenic

1 primary sclerosing cholangitis, ethanol, and cryptogenic.

2 c (e.g., primary biliary cirrhosis), and (3) cryptogenic.

3 ied, and they are often termed idiopathic or cryptogenic.

4 minor-risk echocardiographic abnormalities (cryptogenic 37% vs 45%; p=0.18) or paroxysmal AF (6% vs

5 ould be part of our diagnostic algorithm of "cryptogenic abscesses" since surgical removal of the for

6 d aplastic anemia, and 0 of 17 patients with cryptogenic acute liver failure, compared with 150 (24%)

7 c cortex studied in postsurgical tissue from cryptogenic and FCD patients.

8 e likely susceptibility genes for developing cryptogenic and noncryptogenic forms of liver disease.

9 conditions such as aneurysmal SAH (aSAH) or cryptogenic "angiogram-negative" SAH (cSAH) owing to ove

10 us indications, 44 patients transplanted for cryptogenic, autoimmune, hepatitis B, or cholestatic liv

11 The proportion of cryptogenic cases will decrease with improvements in MRI

12 igin of pneumatosis intestinalis will remain cryptogenic--caused but unexplained.

13 ctive observational studies of patients with cryptogenic cerebral ischemia that provided both sensiti

14 an be detected in up to 43% of patients with cryptogenic cerebral ischemia undergoing investigation w

15 TE for the detection of PFO in patients with cryptogenic cerebral ischemia.

16 Fibrosis scores for cryptogenic, cholestatic, and alcoholic recipients were

17 Autoimmune hepatitis (AIH) and cryptogenic chronic hepatitis (CCH) are important causes

18 Cryptogenic chronic hepatitis is indistinguishable from

19 a diagnosis of AIH to 20 of 21 patients with cryptogenic chronic hepatitis, whereas only five patient

20 rticosteroids can also benefit patients with cryptogenic chronic hepatitis.

21 syndromes include autoimmune cholangitis and cryptogenic chronic hepatitis.

22 included: hepatitis C (24), hepatitis B (9), cryptogenic cirrhosis (1), hemochromatosis (1), and prim

23 y of liver disease was hepatitis C (51%) and cryptogenic cirrhosis (29%).

24 titis (NASH) is an under-recognized cause of cryptogenic cirrhosis (CC) on the basis of higher preval

25 er disease (n=495), alcohol and HCV (n=152), cryptogenic cirrhosis (CC, n=289), nonalcoholic steatohe

26 =8940), HCV+alcohol (n=6066), NASH (n=1368), cryptogenic cirrhosis (CC; n=5856), hepatitis B virus (H

27 he primary diagnosis was hepatitis C (n=16), cryptogenic cirrhosis (n=2), and autoimmune hepatitis (n

28 s (HCV) (n=2), HCV (n=1), alcohol (n=1), and cryptogenic cirrhosis (n=3).

29 al Parenteral Nutrition (TPN)-related (one), cryptogenic cirrhosis (one), and hepatoblastoma (one).

30 tio [OR], 3.2; 95% CI, 1.5-6.6; P =.002) and cryptogenic cirrhosis (OR, 11.1; 95% CI, 1.5-87.4; P =.0

31 n hepatitis C virus (HCV) liver (P <.05) and cryptogenic cirrhosis (P <.01) compared with normal cont

32 proportion of women, a greater prevalence of cryptogenic cirrhosis (P <.05) and diabetes (P <.05), an

33 ipients (2003-2012) transplanted for NASH or cryptogenic cirrhosis (the NASH cohort) without pre-tran

34 on in patients with liver disease, including cryptogenic cirrhosis and fulminant hepatic failure.

35 frequencies after liver transplantation for cryptogenic cirrhosis and hepatitis C (HCV).

36 with liver disease, including patients with cryptogenic cirrhosis and idiopathic fulminant hepatic f

37 gher incidence of liver disease secondary to cryptogenic cirrhosis and Laennec's cirrhosis.

38 idence to HGV infection not being a cause of cryptogenic cirrhosis and not being associated with the

39 rify the role of HGV as a causative agent in cryptogenic cirrhosis by analyzing archival liver tissue

40 r of PI MZ carriers existed in patients with cryptogenic cirrhosis compared with other liver disease

41 Half of the patients with cryptogenic cirrhosis had histologic or clinical feature

42 ns in K18 may be predispose to, or result in cryptogenic cirrhosis in humans.

43 Cryptogenic cirrhosis is a common cause of liver-related

44 HGV infection in patients undergoing OLT for cryptogenic cirrhosis is about 25%.

45 n recipients who undergo transplantation for cryptogenic cirrhosis is similar to that of recipients w

46 t HGV-RNA within the livers of patients with cryptogenic cirrhosis or in the HCC arising within them.

47 he diagnoses of primary biliary cirrhosis or cryptogenic cirrhosis than younger recipients, who were

48 ->leu (H127L) K18 mutation in a patient with cryptogenic cirrhosis that is germline transmitted.

49 s, and Mallory hyaline, and two patients had cryptogenic cirrhosis thought to represent "burned out"

50 HGV infection in recipients transplanted for cryptogenic cirrhosis was 26%.

51 Patients with cryptogenic cirrhosis were less likely to have undergone

52 on were studied: 50 were diagnosed as having cryptogenic cirrhosis while 39 had nonviral chronic live

53 or alcoholic cirrhosis (group I), NASH, and cryptogenic cirrhosis with body mass index greater than

54 blood donors, 15% (5 of 33) of patients with cryptogenic cirrhosis, 27% (3 of 11) of patients with id

55 itis, 6 with alcoholic liver disease, 4 with cryptogenic cirrhosis, 4 with biliary atresia, and 10 no

56 ur groups of recipients: 31 transplanted for cryptogenic cirrhosis, 70 for cholestatic etiologies, 40

57 ic cirrhosis, 52.6%; viral cirrhosis, 21.8%; cryptogenic cirrhosis, 8.4%; autoimmune cirrhosis, 5.8%;

58 ients with a pretransplantation diagnosis of cryptogenic cirrhosis, although the disease was generall

59 ion in the keratin 18 gene in a patient with cryptogenic cirrhosis, but the importance of mutations i

60 (K8K18) mutations are found in patients with cryptogenic cirrhosis, but the role of keratin mutations

61 Cryptogenic cirrhosis, hypertension, and coronary artery

62 Blood donors, patients with cryptogenic cirrhosis, idiopathic fulminant hepatic fail

63 isease for which no cause can be identified, cryptogenic cirrhosis, is a common indication for liver

64 AFLD was also defined by clinical diagnosis (cryptogenic cirrhosis, obese-diabetics with cryptogenic

65 unts for a large proportion of idiopathic or cryptogenic cirrhosis, which is associated with the typi

66 those with NASH, and NASH may be a cause of cryptogenic cirrhosis.

67 s now recognized as the most common cause of cryptogenic cirrhosis.

68 rranted in obese patients with alcoholic and cryptogenic cirrhosis.

69 s is confined to alcoholic liver disease and cryptogenic cirrhosis.

70 -M4 developed 19 months after transplant for cryptogenic cirrhosis.

71 e generally stable after transplantation for cryptogenic cirrhosis.

72 ver disease in the majority of patients with cryptogenic cirrhosis.

73 rrhosis, primary sclerosing cholangitis, and cryptogenic cirrhosis.

74 ng associated with the development of HCC in cryptogenic cirrhosis.

75 derwent orthotopic liver transplantation for cryptogenic cirrhosis.

76 ents infected with HGV who underwent OLT for cryptogenic cirrhosis.

77 tation (mean age, 50 years; M:F, 18:28) with cryptogenic cirrhosis.

78 One patient was diagnosed as cryptogenic cirrhosis.

79 patitis (NASH), hereditary dyslipidaemia, or cryptogenic cirrhosis.

80 ations previously described in patients with cryptogenic cirrhosis: K8 Tyr-53 --> His, K8 Gly-61 -->

81 antly in participants who had idiopathic and cryptogenic CSE (seven [36.8%, 95% CI 19.1-59.0] and 16

82 f subsequent epilepsy is not increased after cryptogenic CSE.

83 nt foramen ovale for secondary prevention of cryptogenic embolism did not result in a significant red

84 The options for secondary prevention of cryptogenic embolism in patients with patent foramen ova

85 c epilepsy had increased risk for idiopathic/cryptogenic epilepsy and for epilepsy associated with ne

86 psy in relatives of probands with idiopathic/cryptogenic epilepsy diminished with increasing age of t

87 Relatives of probands with idiopathic/cryptogenic epilepsy had increased risk for idiopathic/c

88 d POINTER to perform segregation analysis of cryptogenic epilepsy in 1,557 three-generation families

89 The degree of increased risk of idiopathic/cryptogenic epilepsy in relatives of probands with idiop

90 ts suggest that the familial distribution of cryptogenic epilepsy is inconsistent with any convention

91 Prevalence of idiopathic/cryptogenic epilepsy was only 3.7% in newly identified r

92 rs for people with a diagnosis of idiopathic/cryptogenic epilepsy, and the reduction can be up to 10

93 odeficits had increased risks for idiopathic/cryptogenic epilepsy.

94 pathology can be seen in many patients with "cryptogenic" epilepsy.

95 Among 2555 patients, 812 (32%) had cryptogenic events (incidence of cryptogenic stroke 0.36

96 mall vessel subtypes combined, patients with cryptogenic events also had no excess of minor-risk echo

97 atients with large artery events, those with cryptogenic events had less hypertension (adjusted odds

98 ce rates are comparable with other subtypes, cryptogenic events have the fewest atherosclerotic marke

99 pril 1, 2002, to March 31, 2014, we compared cryptogenic events versus other causative subtypes accor

100 The majority of cryptogenic FHF cases cannot be attributed to infection

101 was to evaluate interstitial vascularity in cryptogenic fibrosing alveolitis (CFA) and in fibrosing

102 Lone cryptogenic fibrosing alveolitis (CFA) is a progressive

103 We have previously suggested that cryptogenic fibrosing alveolitis (CFA) may be caused by

104 r was markedly increased among patients with cryptogenic fibrosing alveolitis (rate ratio [RR] 7.31,

105 sed cohort study involving 890 subjects with cryptogenic fibrosing alveolitis and 5, 884 control subj

106 t cigarette smoking may be a risk factor for cryptogenic fibrosing alveolitis as well as for lung can

107 se in lung cancer incidence in patients with cryptogenic fibrosing alveolitis compared with the gener

108 Cryptogenic fibrosing alveolitis has been reported to be

109 of lung cancer is increased in patients with cryptogenic fibrosing alveolitis, and that this effect i

110 ted the possible aetiological role of TTV in cryptogenic fulminant hepatic failure (FHF).

111 the hepatitis G virus (HGV) in patients with cryptogenic fulminant hepatitis (non-A-E FH).

112 However, the cryptogenic group had fewer atherosclerotic risk factors

113 profiles can predict stroke etiology in the cryptogenic group.

114 No etiological role for SENV in the cause of cryptogenic hepatitis could be demonstrated.

115 diseases, viral hepatitis and autoimmunity, cryptogenic hepatitis, and overlap syndromes.

116 est possible candidate virus associated with cryptogenic hepatitis.

117 osteopenia/osteoporosis (52%), anemia (34%), cryptogenic hypertransaminasemia (29%) and recurrent mis

118 The cause of stroke remains unknown or cryptogenic in many patients.

119 s with known biliary tract disease, is often cryptogenic in origin (ie, no clear causal factor can be

120 Pyogenic liver abscess is most often cryptogenic in origin, although sophisticated advanced i

121 mall-vessel or lacunar infarcts, 576 had had cryptogenic infarcts, and 259 had had infarcts designate

122 f ischemic stroke in patients who have had a cryptogenic ischemic stroke is unknown.

123 out known atrial fibrillation, who had had a cryptogenic ischemic stroke or TIA within the previous 6

124 TE) in the detection of PFO in patients with cryptogenic ischemic stroke or transient ischemic attack

125 d a patent foramen ovale (PFO) and had had a cryptogenic ischemic stroke to undergo closure of the PF

126 Among adults who had had a cryptogenic ischemic stroke, closure of a PFO was associ

127 medical therapy for secondary prevention of cryptogenic ischemic stroke.

128 patent foramen ovale in adults who had had a cryptogenic ischemic stroke.

129 a diabetic patient who had three episodes of cryptogenic liver abscess due to Klebsiella pneumoniae.

130 The clustering of cryptogenic liver cirrhosis with IPF suggests that the t

131 d a cluster of individuals (3%) with IPF and cryptogenic liver cirrhosis, another feature of a telome

132 pulmonary fibrosis, bone marrow failure, and cryptogenic liver cirrhosis.

133 irrhosis and dilated cardiomyopathy; one had cryptogenic liver disease and idiopathic cardiomyopathy.

134 In conclusion, hepatitis C and cryptogenic liver disease are the most common etiologies

135 people to liver disease and may account for cryptogenic liver disease in some patients.

136 (cryptogenic cirrhosis, obese-diabetics with cryptogenic liver disease).

137 Of the 55 patients with cryptogenic liver disease, 3 had glycine-to-cysteine mut

138 ts without PVT at listing included: fatty or cryptogenic liver disease, ascites, diabetes mellitus, a

139 ients who undergo liver transplantation have cryptogenic liver disease.

140 m three groups of patients: 55 patients with cryptogenic liver disease; 98 patients with noncryptogen

141 Cryptogenic (of unknown cause) ischaemic strokes are now

142 l (n = 4), and bacterial (n = 5) pneumonias; cryptogenic organizing pneumonia ([COP] n = 4); and pulm

143 Various radiologic patterns of cryptogenic organizing pneumonia (COP) in X-rays have be

144 sociated interstitial lung disease (RB-ILD), cryptogenic organizing pneumonia (COP), acute interstiti

145 olitis-associated interstitial lung disease, cryptogenic organizing pneumonia (idiopathic bronchiolit

146 We also analyzed surgical specimens from cryptogenic patients not presenting structural alteratio

147 aemic strokes are of undetermined cause (ie, cryptogenic), potentially undermining secondary preventi

148 frequency of HAI > or = 2 was more than for cryptogenic recipients at 1 year (52 vs. 29%, P=0.04) an

149 with fibrosis stage >2 was more than that of cryptogenic recipients at 4 months (29 vs. 12%, P=0.05),

150 None of the cryptogenic recipients developed cirrhosis.

151 In 4 of the 11 cryptogenic recipients in whom HGV RNA was detectable in

152 The prevalence of HAI > or = 2 among cryptogenic recipients was similar to that of cholestati

153 Of the five cryptogenic recipients who continue to have measurable H

154 in 60% (3 of 5) of persistently HGV-infected cryptogenic recipients.

155 immunological therapy is sometimes given in cryptogenic refractory status epilepticus.

156 d cell count, many patients can present with cryptogenic shock (shock without hypotension) with more

157 ct of invasive species are frustrated by the cryptogenic status of a large proportion of those specie

158 atent foramen ovale (PFO) is associated with cryptogenic stroke (CS), although the pathogenicity of a

159 2 (32%) had cryptogenic events (incidence of cryptogenic stroke 0.36 per 1000 population per year, 95

160 Cryptogenic stroke accounts for 30% to 40% of ischemic s

161 Of these, 265 patients experienced cryptogenic stroke and 365 experienced known stroke subt

162 We investigated whether patients with cryptogenic stroke and echocardiographic features repres

163 at can help identify potential mechanisms in cryptogenic stroke and patients who may be targeted for

164 potentiator of stroke risk in patients with cryptogenic stroke and PFO is a concomitant atrial septa

165 early 30,000 young patients each year have a cryptogenic stroke and PFO.

166 Cryptogenic Stroke and Underlying Atrial Fibrillation (C

167 Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated

168 or dependency at 6 months was similar after cryptogenic stroke compared with non-cardioembolic strok

169 Detection of atrial fibrillation after cryptogenic stroke has therapeutic implications.

170 of patent foramen ovale among patients with cryptogenic stroke is higher than that in the general po

171 n used for cardiac disorders, but its use in cryptogenic stroke is not well established.

172 e precise role of PFO in the pathogenesis of cryptogenic stroke is not yet established.

173 in the prevention of recurrent stroke after cryptogenic stroke is uncertain.

174 cal therapy versus medical therapy alone for cryptogenic stroke is uncertain.

175 t ischemic stroke in patients who have had a cryptogenic stroke is unknown.

176 In patients with cryptogenic stroke or TIA who had a patent foramen ovale

177 Among patients with a recent cryptogenic stroke or TIA who were 55 years of age or ol

178 18 and 60 years of age who presented with a cryptogenic stroke or transient ischemic attack (TIA) an

179 hing incidental PFOs from pathogenic ones in cryptogenic stroke patients and for identifying patients

180 Three-year monitoring by ICM in cryptogenic stroke patients demonstrated a significantly

181 mized study to report the detection of AF in cryptogenic stroke patients using continuous long-term m

182 The risk was highest among cryptogenic stroke patients, both for large plaques (HR,

183 rences in stroke prevention strategies among cryptogenic stroke patients.

184 pulation is around 25%, but it is doubled in cryptogenic stroke patients.

185 The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) evaluated transesophage

186 pirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), based on the Warfarin-

187 The PFO in Cryptogenic Stroke Study was a 42-center study that eval

188 e more prevalent among patients experiencing cryptogenic stroke than among those with strokes of know

189 n the diagnostic evaluation of patients with cryptogenic stroke to identify potential aetiologies suc

190 The cause of cryptogenic stroke was predicted based on a model develo

191 Patients with prior cryptogenic stroke were randomized to control (n=220) or

192 is suspected (as in patients presenting with cryptogenic stroke) or when an ECG diagnosis of unexplai

193 diagnostic evaluation in 20 to 40% of cases (cryptogenic stroke).

194 When applied to patients with cryptogenic stroke, 17% are predicted to be large-vessel

195 Among patients with PFO and cryptogenic stroke, closure reduced recurrent stroke and

196 re several possible mechanisms implicated in cryptogenic stroke, including occult paroxysmal atrial f

197 In patients with stroke, especially cryptogenic stroke, large aortic plaques remain associat

198 Among patients with a PFO who had had a cryptogenic stroke, the risk of subsequent ischemic stro

199 involving patients with a PFO who had had a cryptogenic stroke, we randomly assigned patients, in a

200 n attempt to quantitate PFO in patients with cryptogenic stroke.

201 troke prevention strategies in patients with cryptogenic stroke.

202 tory comparative studies, and case series on cryptogenic stroke.

203 sure versus medical therapy in patients with cryptogenic stroke.

204 s essential to determine the pathogenesis in cryptogenic stroke.

205 cardiography in the diagnostic evaluation of cryptogenic stroke.

206 (AF) can be a cause of previously diagnosed cryptogenic stroke.

207 n patients with pacemakers and patients with cryptogenic stroke.

208 hophysiology have prompted a reassessment of cryptogenic stroke.

209 w-up for detecting atrial fibrillation after cryptogenic stroke.

210 tecting atrial fibrillation in patients with cryptogenic stroke.

211 may represent an opportunity for those with cryptogenic stroke.

212 ggests a causal relationship between PFO and cryptogenic stroke.

213 Stroke of undetermined aetiology or 'cryptogenic' stroke accounts for 30-40% of ischaemic str

214 There is persuasive evidence that most cryptogenic strokes are thromboembolic.

215 is increasingly accepted that many of these cryptogenic strokes arise from a distant embolism rather

216 Of the cryptogenic strokes predicted to be cardioembolic, 27% w

217 RATIONALE: Cryptogenic strokes, those of unknown cause, have been e

218 vale may prevent a substantial proportion of cryptogenic strokes.

219 ar event rates 14.8% versus 15.4%) or in the cryptogenic subset (P=0.65; hazard ratio 1.17; 95% CI 0.

220 The clinical burden of cryptogenic TIA and stroke is substantial.

221 me, risk factors, and long-term prognosis of cryptogenic TIA and stroke.

222 Cryptogenic was the primary etiology (70%) and the media